School of Life Sciences, Handong Global University, Puk-ku, Pohang City, Kyungbuk 791-708, South Korea.
Int J Antimicrob Agents. 2010 Sep;36(3):230-3. doi: 10.1016/j.ijantimicag.2010.04.007.
DW286 is a novel broad-spectrum fluoroquinolone with excellent antipneumococcal activity. The in vitro activity of DW286 was evaluated against quinolone-susceptible and -resistant Streptococcus pneumoniae and was compared with the activities of reference compounds. Among the tested agents, DW286 showed the most potent antibacterial activity against 94 quinolone-susceptible strains [minimum inhibitory concentration (MIC) 0.008-0.03 mg/L]. Against 23 quinolone-resistant S. pneumoniae with known resistance mechanisms, DW286 also had the lowest MICs of all the tested quinolones [MIC at which 90% of isolates were inhibited (MIC(90))=0.5mg/L], followed by ciprofloxacin, sparfloxacin, moxifloxacin and gemifloxacin. The in vivo activity of DW286 against penicillin-susceptible and -resistant S. pneumoniae was more effective than that of gemifloxacin.
DW286 是一种新型广谱氟喹诺酮类药物，对肺炎链球菌具有优异的抗菌活性。评估了 DW286 对耐氟喹诺酮和敏感肺炎链球菌的体外活性，并与参考化合物的活性进行了比较。在测试的药物中，DW286 对 94 株耐氟喹诺酮敏感菌株表现出最强的抗菌活性（最小抑菌浓度 [MIC] 0.008-0.03mg/L）。对于 23 株具有已知耐药机制的耐氟喹诺酮肺炎链球菌，DW286 也是所有测试的氟喹诺酮类药物中 MIC 最低的（抑制 90%分离株的 MIC（MIC90）=0.5mg/L），其次是环丙沙星、司帕沙星、莫西沙星和加替沙星。DW286 对青霉素敏感和耐药肺炎链球菌的体内活性优于加替沙星。
